Cargando…

Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases

A rebound of osteoclast activity during the 2 years after a treatment or prevention of osteoporosis with denosumab (Dmab) leads to an increased risk of vertebral fractures (VFs). We attempted to identify the risk factors for these VF and to examine the protective role of bisphosphonates. For that, 2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burckhardt, Peter, Faouzi, Mohamed, Buclin, Thierry, Lamy, Olivier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518625/ https://www.ncbi.nlm.nih.gov/pubmed/34009703 http://dx.doi.org/10.1002/jbmr.4335

Ejemplares similares

Raloxifene Has No Efficacy in Reducing the High Bone Turnover and the Risk of Spontaneous Vertebral Fractures after Denosumab Discontinuation
por: Gonzalez-Rodriguez, Elena, et al.
Publicado: (2018)

THU448 Multiple Non-traumatic Vertebral Fractures After Discontinuation Of Denosumab
por: Riahi, Shayan, et al.
Publicado: (2023)

Discontinuation of Denosumab and Associated Fracture Incidence: Analysis From the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial
por: Brown, Jacques P, et al.
Publicado: (2013)

Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study
por: Tutaworn, Teerapat, et al.
Publicado: (2023)

Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: A case report
por: Kashii, Masafumi, et al.
Publicado: (2020)

Observations following discontinuation of long-term denosumab therapy
por: McClung, M. R., et al.
Publicado: (2017)

Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases
por: Dupont, Jolan, et al.
Publicado: (2022)

Effect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women
por: Ha, J., et al.
Publicado: (2022)

Effect of risedronate on bone loss at discontinuation of denosumab
por: Laroche, Michel, et al.
Publicado: (2020)

Bone Health and Denosumab Discontinuation in Oncology Populations
por: Cheung, Yee-Ming Melody, et al.
Publicado: (2022)

Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study
por: Adachi, Jonathan D., et al.
Publicado: (2017)

THU445 Complicated Course And Management After Denosumab Discontinuation: A Case Report
por: Arora, Ipsa, et al.
Publicado: (2023)

Multiple Vertebral Fractures After Denosumab Discontinuation: FREEDOM and FREEDOM Extension Trials Additional Post Hoc Analyses
por: Cosman, Felicia, et al.
Publicado: (2022)

Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review
por: Anastasilakis, Athanasios D., et al.
Publicado: (2021)

Osteoclast Recycling and the Rebound Phenomenon Following Denosumab Discontinuation
por: Kim, Albert S., et al.
Publicado: (2022)

Rebound Vertebral Fractures in a Patient With Lung Cancer After Oncology-Dose Denosumab Discontinuation: A Cautionary Tale
por: Tyan, Alexander, et al.
Publicado: (2019)

Symptomatic Rebound Hypercalcemia After Denosumab Discontinuation in a Pediatric Patient With Cherubism
por: Marpuri, Ian, et al.
Publicado: (2021)

Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of Denosumab
por: Anastasilakis, Athanasios D., et al.
Publicado: (2023)

Hypercalcemia following discontinuation of denosumab therapy: A systematic review
por: Horiuchi, Keisuke, et al.
Publicado: (2021)

Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature
por: Tay, Wei Lin, et al.
Publicado: (2022)

The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids
por: Saag, Kenneth G., et al.
Publicado: (2022)

Reduced osteoprotegerin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation
por: Fu, Qiang, et al.
Publicado: (2023)

Denosumab and atypical femoral fractures
por: Aspenberg, Per
Publicado: (2014)

Preventing Rebound-Associated Fractures after Discontinuation of Denosumab Therapy: A Position Statement from the Health Insurance Committee of the Korean Endocrine Society
por: Kim, Bu Kyung, et al.
Publicado: (2021)

The Decalcification of Cervicothoracic Spinal Metastasis of Breast Cancer Due to Discontinuation of Denosumab: A Case Report
por: Tatsumura, Masaki, et al.
Publicado: (2022)

Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis
por: Suzuki, Takako, et al.
Publicado: (2017)

SAT-532 Bisphosphonates Prevent Bone Loss Associated with Denosumab Treatment Discontinuation
por: Zanchetta, Maria Belen, et al.
Publicado: (2019)

A Multi-Institutional Randomized Controlled Trial to Investigate Whether Zoledronate Prevents Bone Loss After Discontinuation of Denosumab: The Study Protocol of Denosumab Sequential Therapy (DST) Trial
por: Lee, Chia-Che, et al.
Publicado: (2021)

Atypical femoral fracture in a metastatic bone disease patient six months after discontinuation of denosumab received sequentially to previous bisphosphonate therapy - A case report
por: Georgiadis, George F., et al.
Publicado: (2021)

Effectiveness of denosumab for fracture prevention in real-world postmenopausal women with osteoporosis: a retrospective cohort study
por: Lai, E. C.-C., et al.
Publicado: (2022)

Effect of Denosumab and Teriparatide on Fracture Nonunion
por: Boutin, Regine, et al.
Publicado: (2023)

Rebound-associated vertebral fractures may occur in sequential time points following denosumab discontinuation: need for prompt treatment re-initiation
por: Anastasilakis, Athanasios D., et al.
Publicado: (2020)

Persistence with Denosumab in Women at High Risk of Fracture in Bulgaria
por: Monov, Simeon, et al.
Publicado: (2021)

ODP119 Raloxifene use after denosumab discontinuation partially attenuates bone loss in the lumbar spine in postmenopausal osteoporosis
por: Hone, Namki, et al.
Publicado: (2022)

Edition Eulenburg No. 797, Horn Concerto, : Mi♭ majeur - E♭ major - Es dur KV 495 /

Elevated Bone Hardness Under Denosumab Treatment, With Persisting Lower Osteocyte Viability During Discontinuation
por: Jähn-Rickert, Katharina, et al.
Publicado: (2020)

A Review on the Role of Denosumab in Fracture Prevention
por: Pang, Kok-Lun, et al.
Publicado: (2020)

MON-356 Atypical Femur Fracture with Denosumab
por: Mirza, Faryal S, et al.
Publicado: (2020)

797. Tuberculosis Treatment: Combined Forms vs. Dissociated Forms
por: Trigui, Maroua, et al.
Publicado: (2018)

Hypercalcemia upon denosumab withdrawal in primary hyperparathyroidism: a case report and literature review
por: Camponovo, C., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_728lm4451pqm684ak0utc5h206